Advances in the diagnosis and treatment of premenstrual dysphoria

CNS Drugs

Volumn 13, Issue 4, 2000, Pages 287-304

  Steiner, Meir ^a,b   Born, Leslie ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANXIOLYTIC AGENT; BUSERELIN; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DANAZOL; ESTRADIOL; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; MEDROXYPROGESTERONE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRYPTOPHAN;

DIET SUPPLEMENTATION; DRUG INDUCED DISEASE; DYSPHORIA; EXERCISE; FEMALE; HUMAN; MENSTRUAL CYCLE; MENTAL DISEASE; OSTEOPOROSIS; OVARIECTOMY; PHOTOTHERAPY; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REVIEW; SEXUAL DYSFUNCTION;

EID: 0034012327     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200013040-00005     Document Type: Review

References (187)

1. 1. Endicott J, Amsterdam, J, Eriksson E, et al. Is premenstrual dysphoric disorder a distinct clinical entity? J Women's Health Gender-Based Med 1999; 8: 663-79
2. 2. World Health Organization. Tenth revision of the International Classification of Diseases (ICD-10). Geneva: World Health Organization Publishers, 1996: 717
3. 3. Budeiri DJ, Li Wan Po A, Dornan JC. Clinical trials of treatments of premenstrual syndrome: entry criteria and scales for measuring treatment outcomes. Br J Obstet Gynaecol 1994; 101: 689-95
4. 4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987: 367-9
5. 5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994: 717-8
6. 6. Steiner M, Wilkins A, Diagnosis and assessment of premenstrual dysphoria. Psychiatr Ann 1996; 26: 571-5
7. 7. Johnson SR. The epidemiology and social impact of premenstrual symptoms. Clin Obstet Gynecol 1987; 30: 367-76
8. 8. Greene R, Dalton K. The premenstrual syndrome. BMJ 1953; 1: 1007-14
9. 9. Haskett RF, DeLongis A, Kessler RC. Premenstrual dysphoria: a community survey. Presented at Annual American Psychiatric Association Meeting: 1987 May; Chicago
10. 10. Johnson SR, McChesney C, Bean JA. Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behaviour. J Reprod Med 1988; 33: 340-6
11. 11. Rivera-Tovar AD, Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry 1990; 147: 1634-6
12. 12. Andersch B, Wendestam C, Hahn L, et al. Premenstrual complaints. I. Prevalence of premenstrual symptoms in a Swedish urban population. J Psychosom Obstet Gynaecol 1986; 5: 39-49
13. 13. Merikangas KR, Foeldenyi M, Angst J. The Zurich Study. XIX. Patterns of menstrual disturbances in the community: results of the Zurich Cohort Study. Eur Arch Psychiatry Clin Neurosci 1993; 243: 23-32
14. 14. Ramcharan S, Love EJ, Fick GH, et al. The epidemiology of premenstrual symptoms in a population based sample of 2650 urban women. J Clin Epidemiol 1992; 45: 377-81
15. 15. Freeman EW, Sondheimer K, Weinbaum PH, et al. Evaluating premenstrual symptoms in medical practice. Obstet Gynecol 1985; 65: 500-5
16. 16. O'Brien PMS, Abukhalil IEH, Henshaw C. Premenstrual syndrome. Curr Obstet Gynecol 1995; 5: 30-7
17. 17. Hendrick V, Altshuler LL, Burt VK. Course of psychiatric disorders across the menstrual cycle. Harv Rev Psychiatry 1996; 4: 200-7
18. 18. Bailey JW, Cohen LS. Prevalence of mood and anxiety disorders in women who seek treatment for premenstrual syndrome. J Womens Health Gend Based Med 1999; 8: 1181-4
19. 19. Blehar MC, DePaulo Jr JR, Gershon ES, et al. Women with bipolar disorder: findings from the NIMH Genetics Initiative sample. Psychopharmacol Bull 1998; 34: 239-43
20. 20. Yonkers KA. The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry 1997; 58 Suppl. 15: 19-25
21. 21. Yonkers KA. Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders. J Clin Psychiatry 1997; 58 Suppl. 3: 62-7
22. 22. Freeman EW, Rickels K, Schweizer E, et al. Relationships between age and symptom severity among women seeking medical treatment tor premenstrual symptoms. Psychol Med 1995; 25: 309-15
23. 23. Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 1999; 8: 122-8
24. 24. Woods NF, Most A, Dery GK. Prevalence of perimenstrual symptoms. Am J Public Health 1982; 72: 1257-64
25. 25. Hargrove JT, Abraham GE. The incidence of premenstrual tension in a gynecologic clinic. J Reprod Med 1982; 27: 721-4
26. 26. Pearlstein TB, Frank E, Rivera-Tovar A, et al. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord 1990; 20: 129-34
27. 27. Parry BL. Mood disorders linked to reproductive cycle in women. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York (NY): Raven Press, 1995: 1029-42
28. 28. Harrison WM, Endicott J, Nee J, et al. Characteristics of women seeking treatment for premenstrual syndrome. Psychosomatics 1989; 30: 405-11
29. 29. Fava M, Pedrazzi F, Guaraldi GP, et al. Comorbid anxiety and depression among patients with late luteal phase dysphoric disorder. J Anxiety Disord 1992; 6: 325-35
30. 30. McLeod DR, Hoehn-Saric R, Foster GV, et al. The influence of premenstrual syndrome on ratings of anxiety in women with generalized anxiety disorder. Acta Psychiatr Scand 1993; 88: 248-51
31. 31. Endicott J. The menstrual cycle and mood disorders. J Affect Disord 1993; 29: 193-200
32. 32. Bancroft J, Rennie D, Warner P. Vulnerability to perimenstrual mood change: the relevance of a past history of depressive disorder. Psychosom Med 1994; 56: 225-31
33. 33. Kaspi SP, Otto MW, Pollack MH, et al. Premenstrual exacerbation of symptoms in women with panic disorder. J Anxiety Disord 1994; 8: 131-8
34. 34. Graze KK, Nee J, Endicott J. Premenstrual depression predicts future major depressive disorder. Acta Psychiatr Scand 1990; 81: 201-5
35. 35. Condon JT. The premenstrual syndrome: a twin study. Br J Psychiatry 1993; 162: 481-6
36. 36. Kendler KS, Karkowski LM, Corey LA, et al. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 1998; 155: 1234-40
37. 37. Severino SK, Moline ML. Premenstrual syndrome: a clinician's guide. New York (NY): The Guilford Press, 1989: 132-5
38. 38. Paddison PL, Gise LH, Lebovits A, et al. Sexual abuse and premenstrual syndrome: comparison between a lower and higher socioeconomic group. Psychosomatics 1990; 31: 265-72
39. 39. Dan AJ, Monagle L. Sociocultural influences on women's experiences of perimenstrual symptoms. In: Gold JH, Severino SK, editors. Premenstrual dysphorias: myths and realities. Washington, DC: American Psychiatric Press, Inc., 1994: 201-11
40. 40. Chandra PS, Chaturvedi SK. Cultural variations in premenstrual experience. Int J Soc Psychiatry 1989; 35 (4): 343-9
41. 41. Chang AM, Holroyd E, Chau JP. Premenstrual syndrome in employed Chinese women in Hong Kong. Health Care Women Int 1995; 16: 551-61
42. 42. Sveinsdottir H. Prospective assessment of menstrual and premenstrual experiences of Icelandic women. Health Care Women Int 1998; 19: 71-82
43. 43. Marvan ML, Diaz-Erosa M, Montesinos A. Premenstrual symptoms in Mexican women with different educational levels. J Psychol 1998; 132: 517-26
44. 44. Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998; 338: 209-16
45. 45. Casson P, Hahn PM, Van Vugt DA, et al. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 1990; 162: 99-105
46. 46. Casper RF, Hearn MT. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol 1990; 162: 105-9
47. 47. Roca CA, Schmidt PJ, Bloch M, et al. Implications of endocrine studies of premenstrual syndrome. Psychiatr Ann 1996; 26: 576-80
48. 48. Rubinow DR, Schmidt PJ. The treatment of premenstrual syndrome - forward into the past. N Engl J Med 1995; 332: 1574-5
49. 49. Eriksson E, Sundblad C, Lisjo P, et al. Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls. Psychoneuroendocrinol 1992; 17: 195-204
50. 50. Eriksson E, Alling C, Andersch B, et al. Cerebrospinal fluid levels of monoamine metabolites. A preliminary study of their relation to menstrual cycle phase, sex steroids, and pituitary hormones in healthy women and in women with premenstrual syndrome. Neuropsychopharmacol 1994; 11: 201-13
51. 51. Steiner M, Coote M, Wilkins A, et al. Biological correlates of irritability in women with premenstrual dysphoria [abstract]. Eur Neuropsychopharmacol 1997; 7 Suppl. 2: S172
52. 52. Eriksson E, Sundblad C, Landén M, et al. Behavioural effects of androgens in women. In: Steiner M, Yonkers K, Eriksson E, editors. Mood disorders in women. London: Martin Dunitz Ltd, 2000
53. 53. Rowe T, Sasse V. Androgens and premenstrual symptoms - the response to therapy. In: Deneerstein L, Frazer I, editors. Hormones and behaviour. New York (NY): Elsevier Science Publishers, 1986: 160-5
54. 54. Burnet RB, Radden HS, Easterbrook EG, et al. Premenstrual syndrome and spironolactone. Aust NZ J Obstet Gynaecol 1991; 31: 366-8
55. 55. Dougherty DM, Bjork JM, Moeller FG, et al. The influence of menstrual-cycle phase on the relationship between testosterone and aggression. Physiol Behav 1997; 62: 431-5
56. 56. Bäckström T, Aakvaag A. Plasma prolactin and testosterone during the luteal phase in women with premenstrual tension syndrome. Psychoneuroendocrinol 1981; 6: 245-51
57. 57. Rubinow DR, Hoban MC, Grover GN, et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol 1988; 158: 5-11
58. 58. Bloch M, Schmidt PJ, Su TP, et al. Pituitary-adrenal hormones and testosterone across the menstrual cycle in women with premenstrual syndrome and controls. Biol Psychiatry 1998; 43: 897-903
59. 59. Hammarback S, Bäckström T, Holst J, et al. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement therapy. Acta Obstet Gynecol Scand 1985; 64: 393-7
60. 60. Rapkin AJ, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997; 90: 709-14
61. 61. Schmidt PJ, Purdy RH, Moore Jr PH, et al. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 1994; 79: 1256-60
62. 62. Wang M, Seippel L, Purdy RH, et al. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5 α-pregnane-3,20-dione and 3 α-hydroxy-5-alpha-pregnan-20-one. J Clin Endocrinol Metab 1996; 81: 1076-82
63. 63. Bicikova M, Dibbelt L, Hill M, et al. Allopregnanolone in women with premenstrual syndrome. Horm Metab Res 1998; 30: 227-30
64. 64. Muneyvirci-Delale O, Nacharaju VL, Altura BM, et al. Sex steroid hormones modulate serum ionized magnesium and calcium levels throughout the menstrual cycle in women. Fertil Steril 1998; 69: 958-62
65. 65. Thys-Jacobs S, Alvir MJ. Calcium-regulating hormones across the menstrual cycle: evidence of a secondary hyperparathyroidism in women with PMS. J Clin Endocrinol Metab 1995; 80: 2227-32
66. 66. Korzekwa MI, Lamont JA, Steiner M. Late luteal phase dysphoric disorder and the thyroid axis revisited. J Clin Endocrinol Metab 1996; 81: 2280-4
67. 67. Nikolai TF, Mulligan GM, Gribble RK, et al. Thyroid function and treatment inn premenstrual syndrome. J Clin Endocrinol Metab 1990; 70: 1108-12
68. 68. Schmidt PJ, Grover GN, Roy-Byrne PP, et al. Thyroid function in women with premenstrual syndrome. J Clin Endocrinol Metab 1993; 76: 671-4
69. 69. Girdler SS, Pedersen CA, Straneva PA, et al. Dysregulation of cardiovascular and neuroendocrine responses to stress in premenstrual dysphoric disorder. Psychiatry Res 1998; 81: 163-78
70. 70. Woods NF, Lentz MJ, Mitchell ES, et al. Perceived stress, physiologic stress arousal, and premenstrual symptoms: group differences and intra-individual patterns. Res Nurs Health 1998; 21: 511-23
71. 71. Cahill CA. Differences in cortisol, a stress hormone, in women with turmoil-type premenstrual symptoms. Nur Res 1998; 47: 278-84
72. 72. Steiner M, LePage P, Dunn EJ. Serotonin and gender specific psychiatric disorders. Int J Psychiatry Clin Pract 1997; 1: 3-13
73. 73. Rapkin AJ. The role of serotonin in premenstrual syndrome. Clin Obstet Gynecol 1992; 35: 629-36
74. 74. Rojansky N, Halbreich U, Zander K, et al. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Invest 1991; 31: 146-52
75. 75. Steiner M. Female-specific mood disorders. Clin Obstet Gynecol 1992; 35: 599-611
76. 1A receptor subsensitivity a trait marker for late luteal phase dysphoric disorder? A pilot study. Can J Psychiatry 1993; 38: 662-4
77. 77. Wurtman JJ. Depression and weight gain: the serotonin connection. J Affect Disord 1993; 29: 183-92
78. 78. Meltzer HY. Serotonergic dysfunction in depression. Br J Psychiatry 1989; 155 Suppl. 8: 25-31
79. 79. Tuiten A, Panhuysen G. Koppeschaar H, et al. Stress, serotonergic function, and mood in users of oral contraceptives. Psychoneuroendocrinology 1995; 20: 323-34
80. 80. Cohen IR, Wise PM. Effects of estradiol on the diurnal rhythm of serotonin activity in microdissected brain areas of ovariectomized rats. Endocrinology 1988; 122: 2619-25
81. 81. Ladisich W. Influence of progesterone on serotonin metabolism: a possible causal factor for mood changes. Psychoneuroendocrinology 1977; 2: 257-66
82. 82. Ashby Jr CR, Carr LA, Cook CL, et al. Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome. Biol Psychiatry 1988; 24: 225-33
83. 83. Rapkin AJ, Edelmuth E, Chang LC, et al. Whole blood serotonin in premenstrual syndrome. Obstet Gynecol 1987; 70: 533-7
84. 84. Steege JF, Stout AL, Knight DL, et al. Reduced platelet tritium-labeled imipramine binding sites in women with premenstrual syndrome. Am J Obstet Gynecol 1992; 167: 168-72
85. 85. Taylor DL, Mathew RH, Ho BT, et al. Serotonin levels and platelet uptake during premenstrual tension. Neuropsychobiology 1984; 12: 16-8
86. 86. Bancroft J, Cook A, Davidson D, et al. Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change. Psychol Med 1991; 21: 305-12
87. 87. Bancroft J, Cook A. The neuroendocrine response to d-fenfluramine in women with premenstrual depression. J Affect Disord 1995; 36: 57-64
88. 88. Fitzgerald M, Malone K, Li S, et al. Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. Am J Psychiatry 1997; 154: 556-8
89. 89. Steiner M, Yatham LN, Coote M, et al. Serotonergic dysfunction in women with pure premenstrual dysphoric disorder: is the fenfluramine challenge test still relevant? Psychiatry Res 1999; 87: 107-15
90. 90. Su TP, Schmidt PJ, Danaceau M, et al. Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J Clin Endocrinol Metab 1997; 82: 1220-8
91. 91. Menkes DB, Coates DC, Fawcett JP. Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord 1994; 32: 37-44
92. 92. Steiner M, Judge R, Kumar R. Serotonin re-uptake inhibitors in the treatment of premenstrual dysphoria: current state of knowledge. Int J Psychiatry Clin Pract 1997; 1: 241-7
93. 93. Halbreich U, Tworek H. Altered serotonergic activity in women with dysphoric premenstrual syndromes. Int J Psychiatry Med 1993; 23: 1-27
94. 94. Leibenluft E, Fiero PL, Rubinow DR. Effects of the menstrual cycle on dependent variables in mood disorder research. Arch Gen Psychiatry 1994; 51: 761-81
95. 95. Kouri EM, Halbreich U. State and trait abnormalities in women with dysphoric premenstrual syndromes. Psychopharmacol Bull 1997; 33: 767-70
96. 96. Sundstrom I, Andersson A, Nyberg S, et al. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 1998; 67: 126-38
97. 97. Halbreich U, Petty F, Yonkers K, et al. Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. Am J Psychiatry 1996; 153: 718-20
98. 1 protein coupling, phase of menstrual cycle, and prediction of luteal phase symptom severity. Biol Psychiatry 1998; 44: 600-9
99. 99. Mortola JF. Premenstrual syndrome. Trends Endocrinol Metab 1996; 7: 184-9
100. 100. Rupkin AJ, Shoupe D, Reading A, et al. Decreased central opioid activity in premenstrual syndrome: luteinizing hormone response to naloxone. J Soc Gynecol Invest 1996; 3: 93-8
101. 101. Chuong CJ, Coulam CB, Bergstralh EJ, et al. Clinical trial of naltrexone in premenstrual syndrome. Obstet Gynecol 1988; 72: 332
102. 102. Parry BL, Berga SL, Kripke DF, et al. Altered waveform of plasma nocturnal melatonin secretions in premenstrual depression. Arch Gen Psychiatry 1990; 47: 1139-46
103. 103. Parry BL, Berga SL, Mostofi N, et al. Plasma melatonin circadian rhythms during the menstrual cycle and after light therapy in premenstrual dysphoric disorder and normal control subjects. J Biol Rhythms 1997; 12(1): 47-64
104. 104. Parry BL, Udell C, Elliott JA, et al. Blunted phase-shift responses to morning bright light in premenstrual dysphoric disorder. J Biol Rhythms 1997; 12: 443-56
105. 105. Chuong CJ, Kim SR, Taskin O, et al. Sleep pattern changes in menstrual cycles of women with premenstrual syndrome: a preliminary study. Am J Obstet Gynecol 1997; 177: 554-48
106. 106. Nakayama K, Nakagawa T, Hiyama T, et al. Circadian changes in body temperatures during the menstrual cycle of healthy adult females and patients suffering from premenstrual syndrome. Int J Clin Pharmacol Res 1997; 17: 155-64
107. 107. Parry BL, LeVeau B, Mostofi N, et al. Temperature circadian rhythms during the menstrual cycle and sleep deprivation in premenstrual dysphoric disorder and normal comparison subjects. J Biol Rhythms 1997; 12: 34-46
108. 108. Kendler KS, Silberg JL, Neale MC, et al. Genetic and environmental factors in the aetiology of menstrual, premenstrual and neurotic symptoms: a population-based twin study. Psychol Med 1992; 22: 85-100
109. 109. van den Akker OBA, Stein GS, Neale MC, et al. Genetic and environmental variation in menstrual cycle: histories of two British twin samples. Acta Genet Med Gemellol 1987; 36: 541-8
110. 110. Morse G. Positively reframing perceptions of the menstrual cycle among women with premenstrual syndrome. J Obstet Gynecol Neonatal Nurs 1999; 28: 165-74
111. 111. Stotland NL, Harwood B. Social, political, and legal considerations. In: Gold JH, Severino SK, editors. Premenstrual dysphorias: myths and realities. Washington, DC: American Psychiatric Press, 1994: 185-200
112. 112. Marvan ML, Escobedo C. Premenstrual symptomatology: role of prior knowledge about premenstrual syndrome. Psychosom Med 1999; 61: 163-7
113. 113. Fontaine KR, Seal A. Optimism, social support, and premenstrual dysphoria. J Clin Psychol 1997; 53: 243-7
114. 114. Seideman RY. Effects of a premenstrual syndrome education program on premenstrual symptomatology. Health Care Women Int 1990; 11: 491-501
115. 115. Walton J, Youngkin E. The effect of a support group on self-esteem of women with premenstrual syndrome. J Obstet Gynecol Neonatal Nurs 1987; 16: 174-8
116. 116. Kraemer GR, Kraemer RR. Premenstrual syndrome: diagnosis and treatment experiences. J Women's Health 1998; 7: 893-907
117. 117. Rubinow DR, Schmidt PJ, Roca CA. Hormone measures in reproductive endocrine-related mood disorders: diagnostic issues. Psychopharmacol Bull 1998; 34: 289-90
118. 118. Reid RL. Premenstrual syndrome. Curr Probl Obstet Gynecol Fert 1985; 8: 1-57
119. 119. Mortola JF, Girton L, Beck L, et al. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol 1990; 76: 302-7
120. 120. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 1995; 332: 1529-34
121. 121. Steiner M, Haskett RF, Carroll BJ. Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales. Acta Psychiatr Scand 1980; 62: 177-90
122. 122. Steiner M, Streiner DL, Steinberg S, et al. The measurement of premenstrual mood symptoms. J Affect Disord 1999; 53: 269-73
123. 123. Hendrick V, Altshuler LL. Recurrent mood shifts of premenstrual dysphoric disorder can be mistaken for rapid-cycling bipolar II disorder. J Clin Psychiatry 1998; 59: 479-80
124. 124. Macmillan I, Young A. Bipolar II disorder vs. premenstrual dysphoric disorder. J Clin Psychiatry 1999; 60: 409-10
125. 125. Maskall DD, Lam RW, Misri S, et al. Seasonality of symptoms in women with late luteal phase dysphoric disorder. Am J Psychiatry 1997; 154: 1436-41
126. 126. Steiner M, Yonkers K. Depression in women, mood disorders associated with reproductive cyclicity. London: Martin Dunitz Ltd, 1998: 13-20
127. 127. Brockington I. Menstrual psychosis. Arch Women's Ment Health 1998; 1: 3-13
128. 128. Halbreich U. Premenstrual dysphoric disorders: a diversified cluster of vulnerability traits to depression. Acta Psychiatr Scand 1997; 95: 169-76
129. 129. Odber J, Cawood EH, Bancroft J. Salivary cortisol in women with and without perimenstrual mood changes. J Psychosom Res 1998; 45: 557-68
130. 130. Facchinetti F, Tarabusi M, Nappi G. Premenstrual syndrome and anxiety disorders: a psychobiological link. Psychother Psychosom 1998; 67: 57-60
131. 131. Ekholm UB, Ekholm NO, Bäckström T. Premenstrual syndrome: comparison between different methods to diagnose cyclicity using daily symptom ratings. Acta Obstet Gynecol Scand 1998; 77: 551-7
132. 132. Gehlert S, Chang CH, Hartlage S. Establishing the diagnostic validity of premenstrual dysphoric disorder using Rasch analysis. J Outcome Meas 1997; 1: 2-18
133. 133. Gehlert S, Chang CH, Hartlage S. Symptom patterns of premenstrual dysphoric disorder as defined in the DSM-IV. J Womens Health 1999; 8: 75-85
134. 134. Rapkin AJ, Cedars M, Morgan M. Insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in women with premenstrual syndrome. Fertil Steril 1998; 70: 1077-80
135. 135. Parry BL, Mostofi N, Le Veau B, et al. Sleep EEG studies during early and late partial sleep deprivation in premenstrual dysphoric disorder and normal control subjects. Psychiatry Res 1999; 85: 127-43
136. 136. Wyatt KM, Dimmock PW, Jones PW, et al. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ 1999; 318: 1375-81
137. 137. Thys-Jacobs S, Starkey P, Bernstein D, et al. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Am J Obstet Gynecol 1998; 179: 444-52
138. 138. Walker AF, De Souza MC, Vickers MF, et al. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Women's Health 1998; 7: 1157-65
139. 139. Parry BL, Mahan AM, Mostofi N, et al. Light therapy of late luteal phasae dysphoric disorder: an extended study. Am J Psychiatry 1993; 150: 1417-9
140. 140. Parry BL. Light therapy of premenstrual depression. In: Lam RW, editor. Seasonal affective disorder and beyond. Washington, DC: American Psychiatric Press, 1998: 173-91
141. 141. Lam RW, Carter D, Misri S, et al. A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res 1999; 86: 185-92
142. 142. Blake F, Salkovskis P, Gath D, et al. Cognitive therapy for premenstrual syndrome. J Pyschosom Res 1998; 45: 307-18
143. 143. Morse CA, Dennerstein L, Farrell E, et al. A comparison of hormone therapy, coping skills training, and relaxation for the relief of premenstrual syndrome. J Behav Med 1991; 14: 469-89
144. 144. Pearlstein TB. Nonpharmacologic treatment of premenstrual syndrome. Psychiatr Ann 1996; 26: 590-4
145. 145. Morse GG. Effect of positive reframing and social support on perception of perimenstrual changes among women with premenstrual syndrome. Health Care Women Int 1997; 18: 175-93
146. 146. Su T-P, Schmidt PJ, Danaceau MA, et al. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology 1997; 16: 346-56
147. 147. Pearlstein TB, Stone AB, Lund SA, et al. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 1997; 17: 261-6
148. 148. Steiner M, Korzekwa M, Lamont J, et al. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull 1997; 33: 771-4
149. 149. Diegoli MS, da Fonseca AM, Diegoli CA, et al. A double-blind trial of four medications to treat severe premenstrual syndrome. Int J Gynaecol Obstet 1998; 62: 63-7
150. 150. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. JAMA 1997; 278: 983-8
151. 151. Young SA, Hurt PH, Benedek DM, et al. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 1998; 59: 76-80
152. 152. Jermaine DM, Preece CK, Sykes RL, et al. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. Arch Fam Med 1999; 8: 328-32
153. 153. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997; 58: 399-402
154. 154. Freeman EW, Rickels K, Arredondo F, et al. Full-or half-cycle treatment of severe premenstrual syndrome wilh a serotonergic antidepressant. J Clin Psychopharmacol 1999; 19: 3-8
155. 155. Eriksson E, Hedberg MA, Andersch B, et al. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacol 1995; 12: 167-76
156. 156. Sundblad C, Wikander I, Andersch B, et al. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment. Eur Neuropsychopharmacol 1997; 7: 201-6
157. 157. Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998; 18: 390-8
158. 158. Sundblad C, Modigh K, Andersch B, et al. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo controlled trial. Acta Psychiatr Scand 1992; 85: 39-47
159. 159. Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo controlled trial. Neuropsychopharmacol 1993; 9: 133-45
160. 160. Steinberg S, Annable L, Young SN, et al. A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biol Psychiatry 1999; 45: 313-20
161. 161. Harrison WM, Endicott J, Rabkin JG, et al. Treatment of premenstrual dysphoria with alprazolam and placebo. Psychopharmacol Bull 1987; 23: 150-3
162. 162. Smith S, Rinehart JS, Ruddock VE, et al. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover trial. Obstet Gynecol 1987; 70: 37-43
163. 163. Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. Arch Gen Psychiatry 1990; 47: 270-5
164. 164. Berger CP, Presser B. Alprazolam in the treatment of two sub-samples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. Obstet Gynecol 1994; 84: 379-85
165. 165. Freeman EW, Rickels K, Sondheimer SJ, et al. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995; 274: 51-7
166. 166. Rickels K, Freeman E, Sondheimer S. Buspirone in treatment of premenstrual syndrome [letter]. Lancet 1989; 1: 777
167. 167. Brown CS, Ling FW, Farmer RG, et al. Buspirone in the treatment of premenstrual syndrome. Drug Ther 1990; 20 Suppl.: 112-21
168. 168. Sarno AP, Miller Jr EJ, Lundblad EG. Premenstrual syndrome: beneficial effects of periodic low-dose danazol. Obstet Gynecol 1987; 70: 33-6
169. 169. Hahn PM, VanVugt DA, Reid RL. A randomized, placebo-controlled crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 1995; 20: 193-209
170. 170. O'Brien PM, Abukhalil IE. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. Am J Obstet Gynecol 1999; 180 (1 Pt 1): 18-23
171. 171. Brown CS, Ling FW, Andersen RN, et al. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994; 84: 779-86
172. 172. Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 1997; 33: 303-9
173. 173. Mezrow G, Shoupe D. Spicer D, et al. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril 1994; 62: 932-7
174. 174. Hammarback S, Bäckström T. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynaecol Scand 1988; 67: 159-66
175. 175. Bancroft J, Boyle H, Warner P, et al. The use of an LHRH agonist, buserelin, in the long-term management of premenstrual syndromes. Clin Endocrinol 1987; 27: 171-82
176. 176. West CP, Hillier H. Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoludex) in management of the premenstrual tension syndrome. Hum Reprod 1994; 9: 1058-63
177. 177. Smith RN, Studd JW, Zamblera D, et al. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995; 102: 475-84
178. 178. Eriksson E. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Int Clin Psychopharmacol 1999; 14 Suppl. 2: S27-S33
179. 179. Freeman EW, Rickels K, Sondheimer SJ, et al. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 1999; 56: 932-9
180. 180. Schmidt PJ, Grover GN, Rubinow DR. Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1993; 50: 467-73
181. 181. Evans SM, Haney M, Levin FR, et al. Mood and performance changes in women with premenstrual dysphoric disorder: acute effects of alprazolam. Neuropsychopharmacology 1998; 19: 499-516
182. 182. Evans SM, Foltin RW, Fischman MW. Food 'cravings' and the acute effects of alprazolam on food intake in women with premenstrual dysphoric disorder. Appetite 1999; 32: 331-49
183. 183. Sundstrom I, Nyberg S, Bixo M, et al. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand 1999; 78: 891-9
184. 184. Leather AT, Studd JW, Watson NR, et al. The treatment of severe premenstrual syndrome with goserelin with and without 'add-back' estrogen therapy: a placebo-controlled study. Gynecol Endocrinol 1999; 13: 48-55
185. 185. Watson NR, Studd JW, Savvas M, et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989; II: 730-2
186. 186. Bäckström T, Hansson-Malmstrom Y, Lindhe BA, et al. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception 1992; 46: 253-68
187. 187. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992; 36: 257-66